Skip to content

Aeva Technologies AEVA Issuance Of Series A Warrants

Issuance Of Series A Warrants at other companies

Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$409.25K
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
NextNav logo
NextNavNN
-$2.25M
Applied Digital logo
Applied DigitalAPLD
$121.2M+232%
Apollo Global Management logo
Apollo Global ManagementAPO
$0-100%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$0

Other financials

Income statement

See full
Revenue$6.3M+85.9%
Gross profit$1.9M+526%
Operating income-$35.1M-15.5%
Net income-$35.0M-0.3%
EPS (diluted)-$0.56+12.5%

Balance sheet

See full
Cash & equivalents$31.2M+47.0%
Total debt$5.3M+87.4%
Total equity-$12.4M-118%
Total assets$147.3M+28.6%

Cash flow

See full
Operating cash flow-$25.8M+16.1%
CapEx$2.2M+385%
Free cash flow-$28.1M+10.2%

Valuation

See full
Market cap$1.35B+116%
Enterprise value$1.33B+120%
P/S64.5×+3.9×

Profitability

See full
Gross margin-18.5%-7.1pp
Operating margin-630.9%-229pp
Net margin-693.9%-240pp
FCF margin-555.5%-181pp

Returns & leverage

See full
Return on equity-258.4%-589pp
Debt / equity0.4×+0.4×
Current ratio4.1×+1.2×

Where this comes from

Reported directly by Aeva Technologies in its filing.

Tagged under the XBRL concept aeva:IssuanceOfSeriesAWarrants.

The official record: Aeva Technologies’s 10-K, filed March 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aeva Technologies's issuance of series a warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aeva Technologies's issuance of series a warrants?
Aeva Technologies (AEVA) reported issuance of series a warrants of $0 in Q4 2025.
What does issuance of series a warrants mean?
Captures the non-cash impact or accounting recognition associated with the issuance of equity-linked warrants. This provides insight into the company's capital structure and potential future dilution.